October 2, 2025

Supplementary Figure 4 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Flow cytometry analysis highlights the role of CD8 T-cell dysfunction in clear-cell renal cell carcinoma, suggesting new therapeutic targets.

SPP1+ tumor-associated macrophages drive CD8 T-cell dysfunction, leading to immunotherapy resistance.
Flow cytometry results reveal specific gating strategies for identifying SPP1+ TAMs in renal cell carcinoma.
The study focuses on the immunological landscape of clear-cell renal cell carcinoma and its resistance mechanisms.
Identifying TAMs may enhance understanding of treatment responses and inform future therapeutic strategies.

Jiang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Flow cytometry analysis highlights the role of CD8 T-cell dysfunction in clear-cell renal cell carcinoma, suggesting new therapeutic targets.